SRPT : Summary for Sarepta Therapeutics, Inc. - Yahoo Finance

U.S. Markets closed

Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
28.28+0.31 (+1.11%)
At close: 4:00PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close27.97
Bid28.11 x 300
Ask28.50 x 200
Day's Range27.20 - 28.34
52 Week Range8.00 - 63.73
Avg. Volume2,395,898
Market Cap1.54B
PE Ratio (TTM)-5.37
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 3 Biotech Stocks to Buy in February
    Motley Fool3 days ago

    3 Biotech Stocks to Buy in February

    These biotech stocks could put on a clinic in your investment portfolio.

  • American City Business Journals3 days ago

    Santhera opens Mass. office as local Duchenne ecosystem grows

    Swiss drugmaker Santhera Pharmaceuticals has chosen Burlington as the site of its first U.S. office, joining a group of local companies that are developing treatments for Duchenne muscular dystrophy. Santhera said the facility in Burlington would be led by Todd Bazemore, its chief operating officer. Bazemore previously served as a top executive at Dyax, a Burlington biotech that was acquired by Lexington-based Shire in 2015.

  • Benzinga4 days ago

    Oppenheimer Stays Bullish On Sarepta As Concerns Continue To Swirl

    Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT ) have declined sharply, with continued concerns around reimbursement and competition. The shares could appreciate going ahead, driven by “the ongoing eteplirsen ...